Clinical trials: Effects of Immunotherapy
Esophageal Cancer, Chemotherapy Effect
Neoadjuvant Treatment Modalities in Esophageal Cancer
Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year.
- Conditions
- Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery
- Trial name
- NCT04821843
- Testing
- Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Perfusion; Complications, Wound; Foot
Avazzia-University of Texas Southwestern Medical Center-Tennant Biomodulator® PRO Perfusion Study
This study is an open label trial designed to test the effectiveness of the Tennant Biomodulator® PRO electrical stimulation device (Avazzia), which uses BEST™ (Bio-Electric Stimulation Technology), on hospital in-patients to…
- Trial name
- NCT03843307
- Testing
- Avazzia Tennant Biomodulator® PRO
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Avazzia, Inc
Hepatocellular Carcinoma
The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the most common solid malignant tumors. The prognosis of unresectable hepatocellular carcinoma is very poor.
- Trial name
- NCT05760430
- Testing
- PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Patient Reported Outcome Measures, CAR T-Cell Therapy
ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy
This study is designed as a feasibility study implementing electronic Patient Reported Outcomes (ePRO) in CAR T treatment for hematological malignancies, in order to describe AE reporting.
- Trial name
- CARTePRO (NCT05354973)
- Testing
- Consilium CareTM
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- Stiftung Swiss Tumor Institute
Adult Diffuse Large Cell Lymphoma, Recurrent
DPX-Survivac and Checkpoint Inhibitor in DLBCL
This is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two…
- Conditions
- Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- SPiReL (NCT03349450)
- Testing
- DPX-Survivac, Pembrolizumab, Cyclophosphamide 50mg
- Where
- 6 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Sunnybrook Health Sciences Centre
Injection Reactions Site, Systemic Reactions
Can Epinephrine Coated Syringe for Subcutaneous Immunotherapy (SCIT) Reduce Large Local Reaction?
Allergen immunotherapy is effective in the management of allergic asthma, allergic rhinitis/conjunctivitis, and stinging insect hypersensitivity.
- Trial name
- NCT03963115
- Testing
- Epinephrine or normal saline
- Where
- Thailand
- Volunteers
- 17 people
- Sponsor
- Mahidol University
Asthma
Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
In patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab (administered per US product label), when compared to placebo, will provide the participants with significantly improved…
- Trial name
- NCT00691873
- Testing
- Xolair
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Mississippi Medical Center
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Cat Allergy
Exposure Chamber Trial With Cat Immunotherapy
The main purpose of this trial is to investigate if any of three different doses of cat hair immunotherapy is safe for treatment of cat allergic patients.
- Trial name
- NCT00987909
- Testing
- Specific allergen immunotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- ALK-Abelló A/S
Lung Adenocarcinoma, Cryotherapy Effect
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
This study aims to compare the one-year survival benefit of the association of cryoablation-pembrolizumab-pemetrexed-carboplatin versus pembrolizumab-pemetrexed-carboplatin in metastatic lung adenocarcinoma patients.
- Trial name
- CRYOMUNE (NCT04339218)
- Testing
- Cryoablation, Pembrolizumab, Pemetrexed
- Where
- France
- Volunteers
- 214 people
- Sponsor
- Institut Bergonié
Lung Cancer
Supplementation of n-3 PUFA in the Modulation of Lean Mass in Patients With Lung Cancer Receiving a High-protein Diet
This study is conducted to test the hypothesis that patients with lung cancer undergoing treatment with immunotherapy, chemotherapy and tyrosine Kinase Inhibitors receiving a high protein diet and supplemented with fish oil will…
- Trial name
- NCT04965129
- Testing
- Fish oil
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Allergic Rhinitis
Mechanisms of Allergen Immunotherapy
Hay fever (seasonal allergic rhinitis) results from allergy to grass and tree pollen. The majority of affected individuals manage well with medication from the Pharmacy or from their general practitioner (GP), but for some…
- Trial name
- NCT01523158
- Testing
- Allergovit grass or birch
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Royal Sussex County Hospital
Diabetes Mellitus, Type 1
IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)
The IMPACT study is a study to test a new experimental drug, IMCY-0098, for the treatment of type 1 diabetes (T1D). In most people with type 1 diabetes, the pancreas loses its ability to make insulin because some cells of the…
- Trial name
- IMPACT (NCT04524949)
- Testing
- IMCY-0098 450 μg, IMCY-0098 1350 μg
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Imcyse SA
Long-term Effects of Thymosin Alpha 1 Treatment
Long-term Prognosis of Patients With Sepsis After Immunotherapy
Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy.
- Trial name
- NCT04901104
- Testing
- Thymosin Alpha1
- Volunteers
- 900 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Pancreatic Ductal
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.
- Trial name
- NCT02529579
- Testing
- iAPA-DC/CTL adoptive cellular immunotherapy, Gemcitabine
- Where
- China
- Volunteers
- 187 people
- Sponsor
- Changhai Hospital
Food Allergy
The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults
In Finland, the estimated prevalence of physician-diagnosed food allergy in 1-4 year old children is 9%, and the most common allergen is milk. The overall food allergy has been reported to be 3.7%.
- Trial name
- NCT01822353
- Testing
- Dietary supplement
- Where
- Finland
- Volunteers
- 23 people
- Sponsor
- Helsinki University Central Hospital
Squamous Cell Lung Cancer
The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC).
- Trial name
- NCT06647836
- Testing
- Efficacy observation
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma, Chemotherapy Effect
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
The goal of this clinical trial is to compare HAIC concurrently with sequentially combined with targeted and immunotherapies in terms of efficacy and safety in patients with potentially resectable intermediate and advanced HCC…
- Conditions
- Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- HAIC (NCT06041477)
- Testing
- Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Immunotherapy
Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG
The purpose of this prospective pilot clinical study is to evaluate the safety and immunostimulatory effect of intramuscularly administrations of autologous total IgG (autologous total IgG therapy) in healthy subjects and…
- Trial name
- NCT03695757
- Testing
- Part A) Healthy subjects, Part B) Advanced solid tumor
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ajou University School of Medicine
Rhinitis, Allergic, Seasonal
Long-Term Effects of Sublingual Grass Therapy
The purpose of this research study is to investigate whether sublingual immunotherapy (SLIT, grass pollen tablets under the tongue) has long term effects in severe hay fever.
- Trial name
- NCT01335139
- Testing
- Sublingual immunotherapy (SLIT), Subcutaneous immunotherapy (SCIT)
- Where
- United Kingdom
- Volunteers
- 106 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)